Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daiichi Sankyo
Biotech
Deal-hungry Merck plans more phase 3 launches than in 2023
Merck plans to launch more phase 3 trials in 2024 than it did in 2023, underscoring the company's mid- to late-stage growth plan.
Max Bayer
Feb 1, 2024 11:41am
Kronos discontinues mid-stage AML trial after poor response
Dec 19, 2023 11:16am
Chemo drug boosts Daiichi Sankyo ADC in prostate cancer models
Nov 16, 2023 7:35am
Regeneron stays out of ADC deal fray as scientists tinker
Nov 15, 2023 9:11am
Gene editor Metagenomi adds C-suite execs—Chutes & Ladders
Nov 10, 2023 9:30am
Daiichi Sankyo ups revenue forecast thanks to huge Merck deal
Oct 31, 2023 10:10am